Undisclosed Multi-agonist Program

About Pep2Tango Therapeutics

Pep2Tango Therapeutics is an emerging biotech player targeting the massive obesity market with a novel peptide-based therapeutic strategy. The company's core technology involves engineering single-molecule peptides that simultaneously agonize multiple metabolic receptors, a strategy designed to mimic the beneficial effects of natural gut hormones like GLP-1, GIP, and glucagon. By integrating these activities into one molecule, Pep2Tango aims to create drugs that offer greater efficacy in weight reduction, better muscle preservation, and fewer side effects compared to existing single-agonist or co-formulated therapies. As a private, preclinical company, it is positioned to capitalize on the rapid growth and high unmet need in the metabolic disease space.

Therapeutic Areas

Other Obesity Drugs